The Swiss drugmaker expects sales and core earnings per share to grow at constant currencies this year, partly due to the strength of its drug pipeline.
Source link
Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength
Date:
Date:
The Swiss drugmaker expects sales and core earnings per share to grow at constant currencies this year, partly due to the strength of its drug pipeline.
Source link